Gastroenterology
Volume 120, Issue 4 , Pages 946-954 , March 2001

Octreotide for acute esophageal variceal bleeding: A meta-analysis

Received 2 December 1999 ,Accepted 26 October 2000.

References 

  1. Corley DA, Stefan AM, Lee TH. Upper gastrointestinal hemorrhage (UGIH): predicting rebleeding from non-endoscopic clinical parameters. (abstr) Gastroenterology. 1995;108:A9
  2. Avgerinos A. Approach to the management of bleeding esophageal varices: role of somatostatin. Digestion. 1998;59(suppl 1):1–22
  3. Imperiale TF, Teran JC, McCullough AJ. A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology. 1995;109:1289–1294
  4. Gotzsche PC, Gjorup I, Bonnen H, Brahe NE, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ. 1995;310:1495–1498
  5. Avgerinos A, Armonis A, Raptis S. Somatostatin or octreotide versus endoscopic sclerotherapy in acute variceal haemorrhage: a meta-analysis study. (letter) J Hepatol. 1995;22:247–248
  6. Avgerinos A, Armonis A, Raptis S. Somatostatin and octreotide in the management of acute variceal hemorrhage. Hepatogastroenterology. 1995;42:145–150
  7. Ludwig D, Scheadel S, Breuning A, Schiefer B, Stange EF. 48-Hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study. Dig Dis Sci. 2000;45:1019–1027
  8. Schiedermaier P, Brensing KA, Geoke B, Scheatzle T, Sauerbruch T. Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in healthy volunteers. Digestion. 1999;60:132–140
  9. Signorelli S, Negrini F, Paris B, Bonelli M, Girola M. Sclerotherapy with or without somatostatin or octreotide in the treatment of acute variceal haemorrhage: our experience. (abstr) Gastroenterology. 1996;110:A1326
  10. Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med. 1995;333:555–560
  11. Hwang SJ, Lin HC, Chang CF, Lee FY, Lu LCW, Hsia HC, et al. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. J Hepatol. 1992;16:320–325
  12. Huang CC, Sheen IS, Chu CM, Chuah SK, Chien RN, Peng SM, et al. A prospective randomized controlled trial of sandostatin and vasopressin in the management of acute bleeding esophageal varices. Chang Keng I Hsueh. 1992;15:78–83
  13. McKee RF, Garden OJ, Anderson JR, Carter DC. A comparison of SMS 201-995 and oesophageal tamponade in the control of acute variceal haemorrhage. HPB Surg. 1992;6:7–17
  14. Pedretti G, Elia G, Calzetti C, Magnani G, Fiaccadori F. Octreotide versus terlipressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding. Clin Invest. 1994;72:653–659
  15. Sung JJ, Chung SC, Lai CW, Chan FK, Leung JW, Yung MY, et al. Octreotide infusion or emergency sclerotherapy for variceal haemorrhage. [see comments] Lancet. 1993;342:637–641
  16. Sung JJ, Chung SC, Yung MY, Lai CW, Lau JY, Lee YT, et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet. 1995;346:1666–1669
  17. Silvain C, Carpentier S, Sautereau D, Czernichow B, Metreau JM, Fort E, et al. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. Hepatology. 1993;18:61–65
  18. Jenkins SA, Shields R, Davies M, Elias E, Turnbull AJ, Bassendine MF, et al. A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut. 1997;41:526–533
  19. Chan LY, Sung JJ. Review article: the role of pharmaco-therapy for acute variceal haemorrhage in the era of endoscopic haemostasis. Aliment Pharmacol Ther. 1997;11:45–50
  20. Katkov WN. Hold that needle: octreotide for acute variceal hemorrhage. Hepatology. 1994;19:1051–1054
  21. Primignani M, Andreoni B, Carpinelli L, Capria A, Rocchi G, Lorenzini I, et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double-blind, placebo-controlled, multicenter trial. New Italian Endoscopic Club. [see comments] Hepatology. 1995;21:1322–1327
  22. Burroughs A. Double blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial/failures. (abstr) Hepatology. 1996;24:352A
  23. Campisi C, Padula P, Peressini A, Boccardo F, Biraghi M, Casaccia M. Upper digestive hemorrhage. Comparison of terlipressin and octreotide. Minerva Chir. 1993;48:1091–1096
  24. Imperiale TF, Birgisson S. Somatostatin or octreotide compared with H2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Ann Intern Med. 1997;127:1062–1071
  25. Gerbarg ZB, Horwitz RI. Resolving conflicting clinical trials: guidelines for meta-analysis. J Clin Epidemiol. 1988;41:503–509
  26. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17:1–12
  27. Chalmers TC, Celano P, Sacks HS, Smith H. Bias in treatment assignment in controlled clinical trials. N Engl J Med. 1983;309:1358–1361
  28. Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. [see comments] JAMA. 1994;272:125–128
  29. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias.. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–412
  30. Imperiale TF. Meta-analysis: when and how. Hepatology. 1999;29:26S–31S
  31. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis. New York: Oxford University Press; 1994;
  32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  33. Kendall MG, Gibbons JD. Rank correlation methods. New York: Oxford University Press; 1990;
  34. Gleser LJ, Olkin I. Models for estimating the number of unpublished studies. Stat Med. 1996;15:2493–2507
  35. El-Jackie A, Rowaisha I, Waked I, Saleh S, Abdel G. Octreotide vs. sclerotherapy in the control of acute variceal bleeding in schistosomal portal hypertension: a randomized trial. (abstr) Hepatology. 1998;28:553A
  36. Kosumobroto H, Djajapranata LI, Oesman N, Adi P, Nusi IA. Comparison of octreotide, vasopressin and SB tube for acute bleeding of esophageal varices. A prospective randomized trial. (abstr) J Gastroenterol Hepatol. 1994;9:A34
  37. Signorelli S, Paris B, Negrini F, Bonelli M, Auriemma L. Esophageal varices bleeding: comparison between treatment with sclerotherapy alone vs sclerotherapy plus octreotide. (abstr) Hepatology. 1997;26:137A
  38. Zuberi BF, Baloch Q. Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with low-risk cirrhosis. Am J Gastroenterol. 2000;95:768–771
  39. McKee RF. Sandostatin therapy of acute oesophageal variceal bleeding. Digestion. 1993;54(suppl 1):27–29
  40. Lo GH, Lai KH, Cheng JS, Lin CK, Huang JS, Hsu PI, et al. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. (abstr) Hepatology. 1997;25:1101–1104
  41. Heresbach D, Jacquelinet C, Nouel O, Chaperon J, Bretagne JF, Gosselin M. Sclerotherapy versus ligation in hemorrhage caused by rupture of esophageal varices. Direct meta-analysis of randomized trials. Gastroenterol Clin Biol. 1995;19:914–920

☆ Supported in part by American Digestive Health Foundation Outcomes Research Training Award, National Institutes of Health Institutional Training Grant, and National Institutes of Health Mentored Clinical Scientist Award. Two of the authors (D.A.C., J.P.C.) have previously received unrestricted grants from Novartis Pharmaceutica (East Hanover, NJ), the manufacturer of octreotide.

☆☆ Address requests for reprints to: Douglas A. Corley, M.D., M.P.H., S-357, UCSF, Box 0538, San Francisco, California 94143-0538. Fax: (415) 476-0659.

PII: S0016-5085(01)49673-9

Gastroenterology
Volume 120, Issue 4 , Pages 946-954 , March 2001

Article Tools

* Image Usage & Resolution